Loading...

We've got a brand new version of Simply Wall St! Try it out

RavenQuest BioMed

CNSX:RQB
Snowflake Description

Overvalued with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RQB
CNSX
CA$45M
Market Cap
  1. Home
  2. CA
  3. Commercial Services
Company description

RavenQuest BioMed Inc., a cannabis company, focuses on the cannabis production, management services and consulting, and specialized research and development activities. The last earnings update was 86 days ago. More info.


Add to Portfolio Compare Print
  • RavenQuest BioMed has significant price volatility in the past 3 months.
RQB Share Price and Events
7 Day Returns
-6.4%
CNSX:RQB
-0.2%
CA Professional Services
1.3%
CA Market
1 Year Returns
-53.8%
CNSX:RQB
31.1%
CA Professional Services
-0.1%
CA Market
RQB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
RavenQuest BioMed (RQB) -6.4% -11% -32.4% -53.8% - -
CA Professional Services -0.2% -0.8% 1.5% 31.1% 43.3% 81.9%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • RQB underperformed the Professional Services industry which returned 31.1% over the past year.
  • RQB underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
RQB
Industry
5yr Volatility vs Market

Value

 Is RavenQuest BioMed undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for RavenQuest BioMed. This is due to cash flow or dividend data being unavailable. The share price is CA$0.365.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for RavenQuest BioMed's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are RavenQuest BioMed's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:RQB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in CAD CA$-0.30
CNSX:RQB Share Price ** CNSX (2019-09-20) in CAD CA$0.37
Canada Professional Services Industry PE Ratio Median Figure of 5 Publicly-Listed Professional Services Companies 19.66x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of RavenQuest BioMed.

CNSX:RQB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:RQB Share Price ÷ EPS (both in CAD)

= 0.37 ÷ -0.30

-1.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • RavenQuest BioMed is loss making, we can't compare its value to the CA Professional Services industry average.
  • RavenQuest BioMed is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does RavenQuest BioMed's expected growth come at a high price?
Raw Data
CNSX:RQB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Professional Services Industry PEG Ratio Median Figure of 36 Publicly-Listed Professional Services Companies 1.74x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for RavenQuest BioMed, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on RavenQuest BioMed's assets?
Raw Data
CNSX:RQB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in CAD CA$0.17
CNSX:RQB Share Price * CNSX (2019-09-20) in CAD CA$0.37
Canada Professional Services Industry PB Ratio Median Figure of 9 Publicly-Listed Professional Services Companies 2.66x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:RQB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:RQB Share Price ÷ Book Value per Share (both in CAD)

= 0.37 ÷ 0.17

2.16x

* Primary Listing of RavenQuest BioMed.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • RavenQuest BioMed is good value based on assets compared to the CA Professional Services industry average.
X
Value checks
We assess RavenQuest BioMed's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Professional Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Professional Services industry average (and greater than 0)? (1 check)
  5. RavenQuest BioMed has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is RavenQuest BioMed expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as RavenQuest BioMed has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
62.6%
Expected Professional Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is RavenQuest BioMed expected to grow at an attractive rate?
  • Unable to compare RavenQuest BioMed's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare RavenQuest BioMed's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare RavenQuest BioMed's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:RQB Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Professional Services Industry Earnings Growth Rate Market Cap Weighted Average 62.6%
Canada Professional Services Industry Revenue Growth Rate Market Cap Weighted Average 4.8%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:RQB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:RQB Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
CNSX:RQB Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-04-30 1 -6 -32
2019-01-31 1 -9 -33
2018-10-31 1 -11 -30
2018-07-31 2 -13 -10
2018-04-30 1 -7 -8
2018-01-31 1 -3 -4
2017-10-31 0 -2 -3
2017-07-31 0 0
2017-04-30 0 0
2017-01-31 0 0
2016-10-31 0 0
2016-07-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if RavenQuest BioMed is high growth as no earnings estimate data is available.
  • Unable to determine if RavenQuest BioMed is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:RQB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from RavenQuest BioMed Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:RQB Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
CNSX:RQB Past Financials Data
Date (Data in CAD Millions) EPS *
2019-04-30 -0.30
2019-01-31 -0.32
2018-10-31 -0.33
2018-07-31 -0.14
2018-04-30 -0.13
2018-01-31 -0.10
2017-10-31 -0.10
2017-07-31 -0.02
2017-04-30 0.00
2017-01-31 0.00
2016-10-31 0.00
2016-07-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if RavenQuest BioMed will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of RQB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. RavenQuest BioMed's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Commercial Services companies here
  3. RavenQuest BioMed's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess RavenQuest BioMed's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
RavenQuest BioMed has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has RavenQuest BioMed performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare RavenQuest BioMed's growth in the last year to its industry (Professional Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • RavenQuest BioMed does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare RavenQuest BioMed's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare RavenQuest BioMed's 1-year growth to the CA Professional Services industry average as it is not currently profitable.
Earnings and Revenue History
RavenQuest BioMed's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from RavenQuest BioMed Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:RQB Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 0.98 -32.41 10.86 0.08
2019-01-31 0.95 -32.64 12.56 0.04
2018-10-31 1.26 -30.47 11.48 0.08
2018-07-31 1.51 -10.50 7.71 0.08
2018-04-30 1.34 -7.70 5.30 0.08
2018-01-31 0.72 -4.30 1.92 0.04
2017-10-31 0.11 -3.30 0.61
2017-07-31 -0.46 0.24
2017-04-30 -0.10 0.09
2017-01-31 -0.08 0.07
2016-10-31 -0.08 0.07
2016-07-31 -0.09 0.08
2016-04-30 -0.08 0.07
2016-01-31 -0.08 0.07
2015-10-31 -0.08 0.07
2015-07-31 -0.05 0.07
2015-04-30 -0.05 0.07
2015-01-31 -0.06 0.07
2014-10-31 -0.06 0.08
2014-07-31 -0.49 0.08
2014-04-30 -0.49 0.09
2014-01-31 -0.50 0.09
2013-10-31 -0.50 0.09
2013-07-31 0.15 0.07
2013-04-30 0.11 0.11
2013-01-31 0.10 0.12
2012-10-31 0.10 0.12

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if RavenQuest BioMed has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if RavenQuest BioMed has efficiently used its assets last year compared to the CA Professional Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if RavenQuest BioMed improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess RavenQuest BioMed's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Professional Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
RavenQuest BioMed has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is RavenQuest BioMed's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up RavenQuest BioMed's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • RavenQuest BioMed's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • RavenQuest BioMed's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of RavenQuest BioMed's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from RavenQuest BioMed Company Filings, last reported 4 months ago.

CNSX:RQB Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 19.90 15.44 1.30
2019-01-31 20.24 14.68 0.96
2018-10-31 22.39 13.26 0.36
2018-07-31 37.00 12.53 1.36
2018-04-30 31.54 12.32 5.26
2018-01-31 7.25 0.24 2.11
2017-10-31 7.57 0.23 3.38
2017-07-31 -0.76 0.83 0.68
2017-04-30 -0.51 0.11 0.00
2017-01-31 -0.47 0.10 0.00
2016-10-31 -0.45 0.08 0.00
2016-07-31 -0.43 0.08 0.00
2016-04-30 -0.41 0.07 0.00
2016-01-31 -0.39 0.06 0.00
2015-10-31 -0.37 0.05 0.00
2015-07-31 -0.34 0.05 0.00
2015-04-30 -0.33 0.04 0.00
2015-01-31 -0.31 0.04 0.00
2014-10-31 -0.29 0.04 0.01
2014-07-31 -0.29 0.04 0.00
2014-04-30 -0.28 0.04
2014-01-31 -0.26 0.04 0.00
2013-10-31 -0.23 0.03 0.00
2013-07-31 0.20 0.02 0.00
2013-04-30 0.22 0.02 0.00
2013-01-31 0.24 0.00 0.00
2012-10-31 0.27 0.00 0.01
  • RavenQuest BioMed's level of debt (77.6%) compared to net worth is high (greater than 40%).
  • RavenQuest BioMed had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • RavenQuest BioMed has less than a year of cash runway based on current free cash flow.
  • RavenQuest BioMed has less than a year of cash runway if free cash flow continues to grow at historical rates of 112.4% each year.
X
Financial health checks
We assess RavenQuest BioMed's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. RavenQuest BioMed has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is RavenQuest BioMed's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from RavenQuest BioMed dividends.
If you bought CA$2,000 of RavenQuest BioMed shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate RavenQuest BioMed's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate RavenQuest BioMed's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:RQB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Professional Services Industry Average Dividend Yield Market Cap Weighted Average of 25 Stocks 1.7%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:RQB Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as RavenQuest BioMed has not reported any payouts.
  • Unable to verify if RavenQuest BioMed's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of RavenQuest BioMed's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as RavenQuest BioMed has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess RavenQuest BioMed's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can RavenQuest BioMed afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. RavenQuest BioMed has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of RavenQuest BioMed's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
W. Robinson
COMPENSATION CA$661,834
TENURE AS CEO 2 years
CEO Bio

George Robinson has been the Chief Executive Officer and Director of Ravenquest Biomed Inc. since September 2017 and is its President.

CEO Compensation
  • Insufficient data for W. to compare compensation growth.
  • W.'s remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the RavenQuest BioMed management team in years:

1.1
Average Tenure
  • The average tenure for the RavenQuest BioMed management team is less than 2 years, this suggests a new team.
Management Team

W. Robinson

TITLE
CEO, President & Director
COMPENSATION
CA$662K
TENURE
2 yrs

Dave Cross

TITLE
Chief Financial Officer
COMPENSATION
CA$229K
TENURE
2 yrs

Mathieu Mcdonald

TITLE
Head of Corporate Communications
TENURE
0.2 yrs

Andy Schinke

TITLE
Head of Sales & Product Acquisition
TENURE
0.2 yrs

Shayne Taker

TITLE
Head of Orbital Garden Mfg & Procurement
TENURE
0.2 yrs

Marla Ritchie

TITLE
Corporate Secretary
AGE
56
TENURE
2 yrs
Board of Directors Tenure

Average tenure and age of the RavenQuest BioMed board of directors in years:

2
Average Tenure
62
Average Age
  • The average tenure for the RavenQuest BioMed board of directors is less than 3 years, this suggests a new board.
Board of Directors

W. Robinson

TITLE
CEO, President & Director
COMPENSATION
CA$662K
TENURE
2 yrs

Tony Drescher

TITLE
Director
COMPENSATION
CA$365K
AGE
62
TENURE
12.4 yrs

Henk Van Alphen

TITLE
Director
COMPENSATION
CA$264K
AGE
66
TENURE
2 yrs

Jorge Bonet

TITLE
Director
COMPENSATION
CA$264K
TENURE
2 yrs

Chris Bechtel

TITLE
Director
COMPENSATION
CA$264K
AGE
60
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
25. Mar 19 Buy Christopher Bechtel Individual 15. Mar 19 15. Mar 19 350,000 CA$0.60 CA$210,000
10. Oct 18 Sell Christopher Bechtel Individual 09. Oct 18 09. Oct 18 -250,000 CA$1.05 CA$-261,500
X
Management checks
We assess RavenQuest BioMed's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. RavenQuest BioMed has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Investors Should Know About Ravenquest Biomed Inc.'s (CNSX:RQB) Financial Strength

(CNSX:RQB) is a small-cap stock with a market capitalization of CA$70m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Assessing first and foremost the financial health is

Simply Wall St -

What Kind Of Shareholder Owns Most Ravenquest Biomed Inc. (CNSX:RQB) Stock?

A look at the shareholders of Ravenquest Biomed Inc. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … With a market capitalization of CA$73m, Ravenquest Biomed is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

How Many Insiders Sold Ravenquest Biomed Inc (CNSX:RQB) Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Ravenquest Biomed Inc (CNSX:RQB). … Ravenquest Biomed Insider Transactions Over The Last Year. … Christopher Bechtel was the only individual insider to sell shares in the last twelve months

Simply Wall St -

How Financially Strong Is Ravenquest Biomed Inc (CNSX:RQB)?

Ravenquest Biomed Inc (CNSX:RQB) is a small-cap stock with a market capitalization of CA$99m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Assessing first and foremost the financial health is

Simply Wall St -

Ravenquest Biomed Inc (CNSX:RQB): When Will It Breakeven?

Ravenquest Biomed Inc's (CNSX:RQB):. … Ravenquest Biomed Inc., a cannabis company, focuses on the cannabis production, management services and consulting, and specialized research and development activities. … The CA$66.7m market-cap posted a loss in its most recent financial year of -CA$3.3m and a latest trailing-twelve-month loss of -CA$7.7m leading to an even wider gap between loss and breakeven?

Simply Wall St -

Is Ravenquest Biomed Inc (CNSX:RQB) A Financially Sound Company?

Investors are always looking for growth in small-cap stocks like Ravenquest Biomed Inc (CNSX:RQB), with a market cap of CA$75.07m. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

Company Info

Description

RavenQuest BioMed Inc., a cannabis company, focuses on the cannabis production, management services and consulting, and specialized research and development activities. The company operates in two segments, Consulting Business, and Cultivation and Sale of Medical Cannabis. It offers its products under the Lore Cannabis and Bloomera brand names. The company was formerly known as Ravencrest Resources Inc. and changed its name to RavenQuest BioMed Inc. in September 2017. RavenQuest BioMed Inc. was incorporated in 1987 and is based in Vancouver, Canada.

Details
Name: RavenQuest BioMed Inc.
RQB
Exchange: CNSX
Founded: 1987
CA$45,228,449
123,913,559
Website: http://www.rqbglobal.com
Address: RavenQuest BioMed Inc.
580 Hornby Street,
Suite 780,
Vancouver,
British Columbia, V6E 2K3,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX RQB Common Shares Canadian National Stock Exchange CA CAD 02. Oct 2012
OTCPK RVVQ.F Common Shares Pink Sheets LLC US USD 02. Oct 2012
DB 1IT Common Shares Deutsche Boerse AG DE EUR 02. Oct 2012
Number of employees
Current staff
Staff numbers
0
RavenQuest BioMed employees.
Industry
Research and Consulting Services
Commercial Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:33
End of day share price update: 2019/09/20 00:00
Last estimates confirmation: 2019/02/28
Last earnings filing: 2019/06/28
Last earnings reported: 2019/04/30
Last annual earnings reported: 2018/10/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.